+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Arterial Hypertension - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 2228064

Global Pulmonary Arterial Hypertension Market to Reach $10.4 Billion by 2030

The global market for Pulmonary Arterial Hypertension estimated at US$7.1 Billion in the year 2022, is projected to reach a revised size of US$10.4 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2022-2030. Prostacyclin & Prostacyclin Analogs, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Endothelin Receptor Antagonists (ERAs) segment is readjusted to a revised 5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 4.5% CAGR

The Pulmonary Arterial Hypertension market in the U.S. is estimated at US$2.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Select Competitors (Total 46 Featured) -

  • Aires Pharmaceuticals
  • Aria CV Inc.
  • BLES Biochemicals Inc.
  • Corlison Pte. Limited
  • FundaciA³n Colombiana de HipertensiA³n Pulmonar
  • Gradient Denervation Technologies
  • OxiWear
  • Pharmaniaga Berhad
  • Pulmonary Hypertension Association, Inc.
  • SoniVie

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Pulmonary Arterial Hypertension

What is the estimated value of the Global Market for Pulmonary Arterial Hypertension?

The Global Market for Pulmonary Arterial Hypertension was estimated to be valued at $7.1 Billion in 2022.

What is the growth rate of the Global Market for Pulmonary Arterial Hypertension?

The growth rate of the Global Market for Pulmonary Arterial Hypertension is 4.9%, with an estimated value of $10.4 Billion by 2030.

What is the forecasted size of the Global Market for Pulmonary Arterial Hypertension?

The Global Market for Pulmonary Arterial Hypertension is estimated to be worth $10.4 Billion by 2030.

Who are the key companies in the Global Market for Pulmonary Arterial Hypertension?

Key companies in the Global Market for Pulmonary Arterial Hypertension include Aires Pharmaceuticals, Aria CV Inc., BLES Biochemicals Inc., Corlison Pte. Limited, FundaciA³n Colombiana de HipertensiA³n Pulmonar, Gradient Denervation Technologies, OxiWear, Pharmaniaga Berhad, Pulmonary Hypertension Association, Inc. and SoniVie.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Pulmonary Hypertension - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Pulmonary Arterial Hypertension Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 3: World Historic Review for Pulmonary Arterial Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 4: World 16-Year Perspective for Pulmonary Arterial Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Prostacyclin & Prostacyclin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 6: World Historic Review for Prostacyclin & Prostacyclin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 7: World 16-Year Perspective for Prostacyclin & Prostacyclin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Endothelin Receptor Antagonists (ERAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Endothelin Receptor Antagonists (ERAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 10: World 16-Year Perspective for Endothelin Receptor Antagonists (ERAs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for SGC Stimulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for SGC Stimulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: World 16-Year Perspective for SGC Stimulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for PDE-5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for PDE-5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for PDE-5 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Intravenous / Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 21: World Historic Review for Intravenous / Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: World 16-Year Perspective for Intravenous / Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Inhalational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: World Historic Review for Inhalational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: World 16-Year Perspective for Inhalational by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: USA Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: USA 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 29: USA Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: USA Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: USA 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • CANADA
  • Table 32: Canada Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Canada 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 35: Canada Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Canada 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • JAPAN
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 38: Japan Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Japan 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 41: Japan Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Japan 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • CHINA
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 44: China Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: China Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: China 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 47: China Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: China Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: China 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • EUROPE
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 50: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Pulmonary Arterial Hypertension by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Europe 16-Year Perspective for Pulmonary Arterial Hypertension by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Europe 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Europe 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • FRANCE
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 59: France Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: France Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: France 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 62: France Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: France Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: France 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • GERMANY
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 65: Germany Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: Germany 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 68: Germany Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: Germany 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • ITALY
  • Table 71: Italy Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: Italy 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 74: Italy Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Italy 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 77: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: UK Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: UK 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 80: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: UK Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: UK 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 83: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Rest of Europe Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: Rest of Europe 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Rest of Europe Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Rest of Europe 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Pulmonary Arterial Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Asia-Pacific 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Asia-Pacific 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 95: Rest of World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Rest of World Historic Review for Pulmonary Arterial Hypertension by Drug Class - Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Rest of World 16-Year Perspective for Pulmonary Arterial Hypertension by Drug Class - Percentage Breakdown of Value Sales for Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), SGC Stimulators and PDE-5 Inhibitors for the Years 2014, 2023 & 2030
  • Table 98: Rest of World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Rest of World Historic Review for Pulmonary Arterial Hypertension by Route Of Administration - Oral, Intravenous / Subcutaneous and Inhalational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Rest of World 16-Year Perspective for Pulmonary Arterial Hypertension by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Intravenous / Subcutaneous and Inhalational for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aires Pharmaceuticals
  • Aria CV Inc.
  • BLES Biochemicals Inc.
  • Corlison Pte. Limited
  • FundaciA³n Colombiana de HipertensiA³n Pulmonar
  • Gradient Denervation Technologies
  • OxiWear
  • Pharmaniaga Berhad
  • Pulmonary Hypertension Association, Inc.
  • SoniVie